Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
A milestone for Tmalin
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
Astra's clash of the T-cell engager Titans
The Titan CD8-guiding technology seems to have spawned a new variant.
Zelgen’s DLL3 trispecific goes pivotal
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
The month ahead: October’s upcoming events
ESMO and the Triple Meeting approach.
